Atea Pharmaceuticals (AVIR) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 33.3% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $318.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | CTNM |
|---|---|---|
| Share price | $3.96 | $8.68 |
| Market cap | $318.00M | $340.83M |
| 1-day change | +0.76% | -3.98% |
| YTD return | +10.92% | -24.06% |
| 1-year return | +33.33% | -20.69% |
| 5-year return | -51.35% | — |
| EPS (TTM) | $-1.95 | $-1.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-158.35M | $-59.98M |
| 52-week high | $6.45 | $17.79 |
| 52-week low | $2.96 | $6.73 |
| Distance from 52-week high | -38.60% | -51.19% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +127.27% | +146.89% |
| Average volume | 290.60K | 776.03K |
| Shares outstanding | 80.30M | 35.35M |
| Employees | 55 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed CTNM by 54.0 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
AVIR vs CTNM FAQ
Which is bigger, Atea Pharmaceuticals or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $318.00M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or CTNM?
AVIR returned +33.33% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.